FDA and CluePoints Extend Existing Collaboration to Include AI/ML for Quality Assessment
Under the new extension, FDA and CluePoints will enhance CluePoints’ SMART software to address a broader range of regulatory concerns.
The Risk-Based Data Management (RBDM) Revolution
The clinical trials landscape is evolving with more data, increased investment in personalized medicines and a shift toward decentralized and hybrid clinical trials.
Leveraging Machine Learning and Deep Learning for Natural Language Processing in Clinical Data Management
Nicolas Huet, CluePoints Machine Learning Manager, discusses developments in the use of machine learning and deep learning for natural language processing and how it can be pragmatically implemented in clinical data management.
The Future of RBQM Adoption
In the fifth and final part of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints look ahead to the future of risk-based quality management and what adoption will look like.
Potential Pitfalls Without RBQM Adoption
In part 4 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints touch on what risks companies leave themselves susceptible to without the adoption of risk-based approaches.
Increasing Comfortability With Adopting Risk-Based Approaches
In part 3 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints discuss what could be holding stakeholders back from adopting risk-based quality management.
Ken Getz of Tufts CSDD and Steve Young of CluePoints Discuss Stand Out Results from Recent RBQM Study
In part 2 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints highlight what stood out to them from the results of a recent study on RBQM adoption.
Ken Getz of Tufts CSDD Discusses RBQM Study Conducted with CluePoints and PwC
In part 1 of this video interview series with Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints, Getz touches on the findings from a recent study on RBQM adoption.
Clinical Research 2.0 Must Embrace Change
We are at a tipping point in the adoption of Clinical Research 2.0. The evolution of risk-based quality management (RBQM), wider adoption of artificial intelligence (AI) and regulatory updates have set the scene for a new holistic approach to data management.
SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.
